Cancer Science & Therapy

Neil Roskell

Publications

• Commentary
  Economic Analysis: Randomized, Placebo-Controlled Clinical Trial of Dutasteride in Men at High Risk for Prostate Cancer
  Author(s): Costel Chirila, Stephanie R. Earnshaw, Libby Black, Cheryl McDade, Neil Roskell, Paul Shannon, Francesco Montorsi and Gerald L. AndrioleCostel Chirila, Stephanie R. Earnshaw, Libby Black, Cheryl McDade, Neil Roskell, Paul Shannon, Francesco Montorsi and Gerald L. Andriole
  
  Objective: Given the economic burden of prostate cancer (PCa), a PCa risk-reduction medication would be desirable. A within-trial economic analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was performed. Methods: REDUCE, a 4-year, randomized, double-blind, placebo-controlled, parallel-group clinical trial, compared efficacy and safety of dutasteride 0.5 mg daily and placebo to reduce the risk of PCa in men at increased risk. Resource use was prospectively collected; costs from standard costing sources were applied. Utilities were obtained from published literature. Relative risks and Wilcoxon rank sums were used to examine differences between treatments. Results: Placebo patients were at significantly higher risk (P < 0.05) for concomitant medication use; and health care visits relate.. Read More»
  DOI: 10.4172/1948-5956.S3-004

  Abstract PDF